Ajax Loader Gif

Ajax Loader Gif

Status: Open
For Patients with Newly Diagnosed Liver Cancer.

A Phase 3 Randomized, Open-Label Study Comparing Pexa‑Vec (Vaccinia GM‑CSF/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

Arm A
Pexa-Vec injected into 1- 5 intrahepatic tumors using imaging-guidance (ultrasound and/or CT). All viable, safely injectable tumors ≥1cm LD must be treated, with a maximum of 5 tumors, treated on a given treatment day. Sorafenib treatment initiated at week 6 or 2 weeks after the last IT injection (whichever is later) and no earlier than week 6

Arm B
Sorafenib will be started at Day 1 at a dose of 400 mg BID. Dosing reductions may be performed according to the registered SmPC


Status: Open
For Patients with Newly Diagnosed Liver Cancer and Failing Sorafenib Treatment

Study to Evaluate the Effectiveness, Safety and Tolerability of
Nivolumab and the Combination Nivolumab Plus Ipilimumab in Subjects With Advanced Liver Cancer
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus (HCV)-infected HCC subjects, and hepatitis B virus (HBV)-infected subjects). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts. A third cohort has been added in this study to compare the efficacy of nivolumab and sorafenib in the treatment of Advanced HCC. A fourth cohort will generate data on the safety and efficacy of the combination nivolumab plus ipilimumab in the treatment of Advanced HCC.
Status: On Hold

Autologous prime-boost anti-tumor vaccination in patients with hepatoma or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the liver
http://clinicaltrials.gov/ct2/show/NCT00553683

This is a phase I/IIa clinical trial using 1) low dose cyclophosphamide to reduce tumor driven immune tolerance, 2) low dose 3D conformational radiation to the tumor, to increase expression of tumor antigens, 3) injection of an immune adjuvant, the toll like receptor III agonist, Poly IC:LC, into and around the tumor to activate the body’s immune defenses, and 4) tumor ablation to reduce production of tumor promoting and immunosuppressive factors. This sequence is referred to as the “Prime”. Patients are then subject to systemic administration of the immune adjuvant to “Boost” the anti-tumor immune response. A full description is available at clinicaltrials.gov Protocol ID NCT00553683

Inclusion Criteria:
1. Over 18 years of age2.
2. Histologically confirmed hepatocellular or metastatic pancreatic carcinoma
3. Radiologically measurable primary, recurrent or metastatic disease confined to the liver.
4. Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occassional help from others).
5. Normal hematologic, renal and liver function (i.e. Absolute neutrophil count > 1500/mm3, Platelets > 75,000/mm3, creatinine ≤ 1.7 mg/dl, total bilirubin ≤ 1.5 mg/dl, transaminases ≤ 3 times above the upper limits of the institutional normal, INR < 1.5.
6. Must be able to provide written informed consent.
7. Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. While animal testing has been negative, the anti-proliferative activity of poly IC may theoretically be harmful to the developing fetus or nursing infantExclusion Criteria

Exclusion Criteria:
1. Serious concurrent infections or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
2. Left ventricular ejection fraction <50%
3. Pregnancy or breast-feeding. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus or nursing infant.
4. Primary or recurrent disease that can be surgically resected leaving the patient disease-free

Contact our study research associate Ismael Castaneda MD at 973-972-6812 or call myself at 973-972-0607 for more information
Status: Closed

Sorafenib pre-treatment in patients undergoing Hepatic Arterial Chemo-Embolization (HACE) for unresectable hepatoma to increase tumor kill.
http://clinicaltrials.gov/ct2/show/NCT00949182

Sorafenib tosylate (Nexavar®), a small molecule Raf kinase and VEGF receptor kinase inhibitor, is FDA approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC). However, further data are needed to determine the optimal combination with resection or ablative treatment the maximize survival advantage.

The liver disease center at the New Jersey Medical School is recruiting patients for a pilot phase II clinical trial to assess the use of sorafenib to reduce micro angiogenesis prior to hepatic-arterial-chemo-embolization (HACE) macro-arteriolar blockade. Patient are treated with 14 days of Sorafenib prior to HACE, and Sorafenib is continued after HACE. Sorafenib is continued through out subsequent HACE treatments. Out come measures are safety, number of HACE treatments to obtain a complete response, time to progression and progression free survival.

Any patient with HCC who is eligible for HACE is eligible for this protocol. A full description will available at ClinicalTrials.gov protocol ID NCT00949182

Contact our study research associate Ismael Castaneda MD at 973-972-6812 or call myself at 973-972-0607 for more information

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery

Ajax Loader Gif

Status: Open

Study of Gemcitabine/Abraxane + PEGPH20 vs Gemcitabine/Abraxane in Stage IV Previously Untreated Pancreatic Cancer

http://clinicaltrials.gov/ct2/show/NCT01839487

PEGPH20 is a PEGylated version of human recombinant PH20 hyaluronidase that, in preclinical studies, has been shown to remove hyaluronan from the extracellular matrix surrounding tumor cells by depolymerizing this substrate. 87% of pancreatic ductal adenocarcinomas (PDA) overexpress HA. PDA tumor tissue may be especially sensitive to the HA-degradation properties of PEGPH20 and thus more responsive to the cytotoxic effects of a given dose of gemcitabine. Modifying the extracellular environment to increase the penetration and efficacy of anti-cancer agents represents a novel approach to treating pancreatic cancer and may provide important therapeutic outcomes in patients with Stage IV Previously Untreated Pancreatic Cancer.


Status: On Hold

Autologous prime-boost anti-tumor vaccination in patients with hepatoma or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the liver
http://clinicaltrials.gov/ct2/show/NCT00553683

This is a phase I/IIa clinical trial using 1) low dose cyclophosphamide to reduce tumor driven immune tolerance, 2) low dose 3D conformational radiation to the tumor, to increase expression of tumor antigens, 3) injection of an immune adjuvant, the toll like receptor III agonist, Poly IC:LC, into and around the tumor to activate the body’s immune defenses, and 4) tumor ablation to reduce production of tumor promoting and immunosuppressive factors. This sequence is referred to as the “Prime”. Patients are then subject to systemic administration of the immune adjuvant to “Boost” the anti-tumor immune response. A full description is available at clinicaltrials.gov Protocol ID NCT00553683

Inclusion Criteria:
1. Over 18 years of age2.
2. Histologically confirmed hepatocellular or metastatic pancreatic carcinoma
3. Radiologically measurable primary, recurrent or metastatic disease confined to the liver.
4. Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occassional help from others).
5. Normal hematologic, renal and liver function (i.e. Absolute neutrophil count > 1500/mm3, Platelets > 75,000/mm3, creatinine ≤ 1.7 mg/dl, total bilirubin ≤ 1.5 mg/dl, transaminases ≤ 3 times above the upper limits of the institutional normal, INR < 1.5.
6. Must be able to provide written informed consent.
7. Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. While animal testing has been negative, the anti-proliferative activity of poly IC may theoretically be harmful to the developing fetus or nursing infantExclusion Criteria

Exclusion Criteria:
1. Serious concurrent infections or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
2. Left ventricular ejection fraction <50%
3. Pregnancy or breast-feeding. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus or nursing infant.
4. Primary or recurrent disease that can be surgically resected leaving the patient disease-free

Contact our study research associate Ismael Castaneda MD at 973-972-6812 or call myself at 973-972-0607 for more information

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery

liver cancer treatment in new jersey, liver cancer surgery in new jersey, pancreas cancer surgery in new jersey, bile duct cancer surgery in new jersey, hepatobiliary surgery in new jersey, pancreatitis surgery in new jersey, portal hypertension care in new jersey, mesocaval shunt in new jersey, laparoscopic liver surgery, laparoscopic pancreas surgery, laparoscopic hepatobiliary surgery


For an Appointment

Dr de la Torre is no longer with
St Joseph’s

Phone: coming soon
Fax: coming soon






Offices: coming soon